Intelligence / Semaglutide

Semaglutide

Prescription Only
GLP-1 Agonist
Schedule
S4
Prescription Only
Enforcement
Tightening
Low Risk
Providers
12
Access: Clear
Key Facts
Schedule 4 - Prescription Only
GLP-1 receptor agonist
TGA-approved branded products available
Compounded versions under increased scrutiny
Import restrictions tightened February 2026

Overview

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management. It is available in Australia as branded products (Ozempic, Wegovy) and through compounding pharmacies. The TGA has increased regulatory scrutiny on compounded versions following supply shortages.

Australian Scheduling

Schedule 4 (Prescription Only). TGA-approved branded products are listed on the ARTG. Compounded semaglutide is available under pharmacy compounding exemptions. Import restrictions were tightened in February 2026.

Access Pathway

Available through telehealth clinics and compounding pharmacies. Branded versions (Ozempic, Wegovy) can be prescribed by any GP. Compounded versions are available through specialised providers but face increasing regulatory scrutiny.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.
Internal medicine (Tokyo, Japan)15 Oct 2026
Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.
Diabetes, obesity & metabolism14 Oct 2026
Emerging therapies for knee osteoarthritis.
Nature reviews. Rheumatology14 Oct 2026
Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series.
JPGN reports12 Oct 2026
"Ozempic Face" and Facial Aging.
Clinics in dermatology10 Oct 2026
Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.
The Journal of clinical endocrinology and metabolism10 Oct 2026
Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.
JACC. Advances9 Oct 2026
The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.
Expert review of clinical immunology8 Oct 2026
Ischemic colitis associated with oral semaglutide with recurrence upon rechallenge.
Revista espanola de enfermedades digestivas8 Oct 2026
Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.
BMJ medicine8 Oct 2026
Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS/MS for doping control purposes.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences8 Oct 2026
Effects of a GLP-1 agonist and anti-diabetic therapies on pheochromocytoma/paraganglioma growth.
Endocrine-related cancer7 Oct 2026
The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment.
Obesity (Silver Spring, Md.)7 Oct 2026
GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery7 Oct 2026
Correction to: Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology6 Oct 2026
Medicaid's GLP-1 Coverage Gap: A Familiar and Correctable Policy Failure.
Medical care6 Oct 2026
In brief: A cardiovascular indication for tirzepatide (Mounjaro).
The Medical letter on drugs and therapeutics5 Oct 2026
Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide.
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir5 Oct 2026
Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
J Diabetes Metab Disord5 Oct 2026
Quantifying Medicare prescription payment plan benefits under Medicare Part D.
Journal of the American Pharmacists Association : JAPhA3 Oct 2026

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.